ClinicalTrials.gg
Active, not recruitingNCT06672978Updated Sep 10, 2026

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis

A Phase 2 interventional study of Meropenem-Vaborbactam and Antibiotics in Acute Pyelonephritis and Complicated Urinary Tract Infection, sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC). Active, not recruiting at 26 sites in 6 countries. Open to participants aged 3 Months to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (part of CorMedix Therapeutics) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Non-randomized
Ages
3 Months to 11 Years
Sex
All
01

Study summary

The primary objective of the study is to assess the safety and tolerability of meropenem-vaborbactam administered by intravenous (IV) infusion in children 3 months and above to less than 12 years with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).

02

Conditions studied

  • Acute Pyelonephritis
  • Complicated Urinary Tract Infection
03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's planned enrollment of 66 is below the median of 175 across 62 interventional studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted before Rempex became part of CorMedix Therapeutics.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a clinically suspected and/or bacteriologically documented cUTI or AP judged by the Investigator to require hospitalization for treatment with at least 3 days of IV antibiotics.
  • Evidence of pyuria, confirmed by either of the following:

    • A urine specimen that is positive for leukocyte esterase via urine dipstick or urinalysis, or
    • A urine specimen with either > 10 white blood cells (WBCs) per microliter from an unspun urine or > 5 WBCs per high power field from a centrifuged specimen
  • Symptomatic or asymptomatic cUTI or AP as specified in the protocol.
  • Acute Pyelonephritis (qualifying symptoms specified in protocol).
  • Have a pretreatment "baseline" urine specimen obtained for culture by an acceptable method, including suprapubic aspiration (SPA), clean urethral catheterization, in dwelling urethral catheter, or mid-stream clean catch (urine specimens obtained from externally placed urine bags will not be allowed) within 48 hours before the start of the administration of the first dose of IV study drug therapy.
  • Must, based on the judgment of the Investigator, require hospitalization initially and 7 to14 days of antibacterial therapy for the treatment of the presumed cUTI.

Key Exclusion Criteria:

  • History of or allergic reaction to beta-lactam antibiotics (for example [e.g.], cephalosporins, penicillins, carbapenems, monobactams).
  • Known Vabomere-resistant gram-negative organism from study-qualifying urine or blood culture, confirmed cUTI or AP only due to gram-positive organism from study-qualifying urine or blood culture, or known or suspected infection with organisms that are not adequately covered by Vabomere (e.g., viral, mycobacterial, fungal).
  • Receipt of a potentially effective antibacterial drug therapy for cUTI for a duration of more than 24 hours during the previous 72 hours prior to enrollment. Exceptions: participants with unequivocal clinical evidence of treatment failure (that is, worsening signs and symptoms); urine culture confirms resistance to the initial antibiotic; or the participant developed signs and symptoms of cUTI or AP while on antibiotics for another indication.
  • Participants undergoing dialysis or with estimated (eGFR) \< 30 mL/minute/1.73 m\^2, as calculated using the updated bedside Schwartz formula.
  • Evidence of significant hepatic disease or dysfunction, including known acute viral or inactive chronic hepatitis or hepatic encephalopathy, or or alanine aminotransferase > 3 × upper limit normal (), or total > 1.5 × ULN.

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
66 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Age 6 to < 12 years

    Participants will receive meropenem-vaborbactam via an IV infusion for a minimum of 3 days, for up to 14 days. Participants with clinical improvement have the option to switch to an oral antibiotic or home IV therapy after Day 3.

    Drug: Meropenem-Vaborbactam · Drug: Antibiotics

  • Experimental
    Cohort 2: Age 2 to < 6 years

    Participants will receive meropenem-vaborbactam IV infusion for a minimum of 3 days, for up to 14 days. Participants with clinical improvement have the option to switch to an oral antibiotic or home IV therapy after Day 3.

    Drug: Meropenem-Vaborbactam · Drug: Antibiotics

  • Experimental
    Cohort 3: Age 3 months to < 2 years

    Participants will receive meropenem-vaborbactam IV infusion for a minimum of 3 days, for up to 14 days. Participants with clinical improvement have the option to switch to an oral antibiotic or home IV therapy after Day 3.

    Drug: Meropenem-Vaborbactam · Drug: Antibiotics

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to 28 days

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Time frame: Day 1 and Day 3: Up to 3 hours post-dose

  2. Time to Maximum Observed Plasma Concentration (Tmax)

    Time frame: Day 1 and Day 3: Up to 3 hours post-dose

  3. Area Under the Plasma Concentration Curve from Zero to Infinity (AUC0-inf)

    Time frame: Day 1 and Day 3: Up to 3 hours post-dose

  4. Overall Response (OR)

    OR as assessed by the combined per-participant clinical cure and favorable microbiological response.

    Time frame: Up to 14 days

  5. Clinical Cure

    Clinical cure is defined as the complete resolution or significant improvement of signs and symptoms of cUTI or AP present at baseline, no new symptoms, and participant is alive.

    Time frame: Up to 14 days

  6. Favorable Microbiological Response (Microbiological Eradication)

    Favorable microbial response is defined as the reduction of baseline pathogen(s) (\< 10\^3 colony-forming units per milliliter \[CFU/mL\] and at least 1-log reduction from baseline) or negative urine culture, negative repeated blood culture if blood culture was positive for pathogen(s) growth at baseline, and participant is alive.

    Time frame: Up to 14 days

07

Study locations

26 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202-3591, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • University of Nebraska Medical Center, Department of Pediatrics
    Omaha, Nebraska 68198, United States
  • University Hospitals Rainbow Babies & Children's Hospital
    Cleveland, Ohio 44106, United States
  • Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski - 2003" OOD, Department of Pediatric Diseases
    Dupnitsa, 2600, Bulgaria
  • Multiprofile Hospital for Active Treatment "Dr. Tota Venkova", Gabrovo, Department of Pediatrics Diseases
    Gabrovo, 5300, Bulgaria
  • Multiprofile Hospital for Active Treatment - Pazardzhik, Second Department of Pediatric Diseases
    Pazardzhik, Bulgaria
  • University Multipurpose Hospital for Active Treatment "Sveti Georgi", Pediatrics Clinic
    Plovdiv, Bulgaria
  • University Multiprofile Hospital for Active Treatment 'Kanev', Ruse, Department of Pediatrics
    Rousse, Bulgaria
  • Multiprofile Hospital for Active Treatment "Dr. Ivan Seliminski", Sliven
    Sliven, Bulgaria
  • Multiprofile Hospital For Active Treatment, "Vita", Department of Urology
    Sofia, Bulgaria
  • University Hospital for Active Treatment and Emergency Medicine (UHATEM) "N. I. Pirogov" LTD, Urology Clinic, Department of Urology
    Sofia, Bulgaria
  • University Hospital for Infectious Diseases "Dr. Fran Mihaljevic"
    Zagreb, 10000, Croatia
  • JSC Vian
    Batumi, Georgia
  • Geo Hospitals LLC
    Tbilisi, 0144, Georgia
  • JSC Georgian Clinics
    Tbilisi, 0159, Georgia
  • LTD L. Managadze National Center of Urology
    Tbilisi, Georgia
  • New Hospitals LLC
    Tbilisi, Georgia
  • Vian JSC
    Tbilisi, Georgia
  • University Hospital Alexandroupolis, Department of Pediatrics
    Alexandroupoli, Greece
  • Agia Sofia Children's Hospital, Infectious Diseases, Pediatrics - General
    Athens, 11527, Greece
  • University General Hospital "Attikon", 1 Rimini Str., Chaidari, PC 12462
    Athens, Greece
  • General Hospital of Thessaloniki "Ippokratio"
    Thessaloniki, 54642, Greece
  • Papageorgiou General Hospital
    Thessaloniki, Greece
  • St. Jadwiga the Queen Provincial Hospital #2 in Rzeszow, 1st Teaching Department of Pediatrics and Pediatric Gastroenterology, Pediatric Cardiology Subdivision
    Rzeszów, 35-301, Poland
  • St. Hedwig of Silesia Hospital in Trzebnica, Pediatric Department with Infantible Sub-department
    Trzebnica, 55-100, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 4, 2024
StartActual
Jun 3, 2025
Primary completionEst.
Jan 2027
CompletionEst.
Jul 2027
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06672978
Collaborators
Biomedical Advanced Research and Development Authority
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Jun 3, 2025
Primary completion
Jan 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 10, 2026

Study contacts

Medical Information
study director · Melinta Therapeutics, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meropenem and vaborbactam

Start the discussion